EA202190614A1 - Конъюгат паклитаксела и гиалуроновой кислоты в лечении мышечно-неинвазивного рака мочевого пузыря - Google Patents

Конъюгат паклитаксела и гиалуроновой кислоты в лечении мышечно-неинвазивного рака мочевого пузыря

Info

Publication number
EA202190614A1
EA202190614A1 EA202190614A EA202190614A EA202190614A1 EA 202190614 A1 EA202190614 A1 EA 202190614A1 EA 202190614 A EA202190614 A EA 202190614A EA 202190614 A EA202190614 A EA 202190614A EA 202190614 A1 EA202190614 A1 EA 202190614A1
Authority
EA
Eurasian Patent Office
Prior art keywords
paclitaxel
treatment
hyaluronic acid
bladder cancer
prodrug
Prior art date
Application number
EA202190614A
Other languages
English (en)
Russian (ru)
Inventor
Джорджо Москони
Даниела Ябес
Карло Пиццокаро
Original Assignee
Фидия Фармачеутичи С.П.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фидия Фармачеутичи С.П.А. filed Critical Фидия Фармачеутичи С.П.А.
Publication of EA202190614A1 publication Critical patent/EA202190614A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EA202190614A 2018-10-25 2019-10-23 Конъюгат паклитаксела и гиалуроновой кислоты в лечении мышечно-неинвазивного рака мочевого пузыря EA202190614A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT102018000009731A IT201800009731A1 (it) 2018-10-25 2018-10-25 Coniugato paclitaxel - acido ialuronico nel trattamento del carcinoma vescicale non infiltrante
PCT/IB2019/059073 WO2020084525A1 (en) 2018-10-25 2019-10-23 Paclitaxel-hyaluronic acid conjugate in the treatment of non-muscle invasive bladder cancer

Publications (1)

Publication Number Publication Date
EA202190614A1 true EA202190614A1 (ru) 2021-06-03

Family

ID=65324453

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202190614A EA202190614A1 (ru) 2018-10-25 2019-10-23 Конъюгат паклитаксела и гиалуроновой кислоты в лечении мышечно-неинвазивного рака мочевого пузыря

Country Status (21)

Country Link
US (4) US20200397909A1 (cg-RX-API-DMAC7.html)
EP (1) EP3870233B1 (cg-RX-API-DMAC7.html)
JP (1) JP7518815B2 (cg-RX-API-DMAC7.html)
KR (1) KR102913965B1 (cg-RX-API-DMAC7.html)
CN (2) CN119792555A (cg-RX-API-DMAC7.html)
CA (1) CA3112188A1 (cg-RX-API-DMAC7.html)
DK (1) DK3870233T3 (cg-RX-API-DMAC7.html)
EA (1) EA202190614A1 (cg-RX-API-DMAC7.html)
ES (1) ES2971217T3 (cg-RX-API-DMAC7.html)
FI (1) FI3870233T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20240188T1 (cg-RX-API-DMAC7.html)
HU (1) HUE066288T2 (cg-RX-API-DMAC7.html)
IT (1) IT201800009731A1 (cg-RX-API-DMAC7.html)
LT (1) LT3870233T (cg-RX-API-DMAC7.html)
MA (1) MA63879B1 (cg-RX-API-DMAC7.html)
PL (1) PL3870233T3 (cg-RX-API-DMAC7.html)
PT (1) PT3870233T (cg-RX-API-DMAC7.html)
RS (1) RS65193B1 (cg-RX-API-DMAC7.html)
SI (1) SI3870233T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400021T1 (cg-RX-API-DMAC7.html)
WO (1) WO2020084525A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202000007747A1 (it) 2020-04-10 2021-10-10 Fidia Farm Spa Coniugato acido ialuronico-paclitaxel nel trattamento del mesotelioma
IT202000008209A1 (it) * 2020-04-17 2021-10-17 Fidia Farm Spa Procedimento di sintesi di un coniugato acido ialuronico-paclitaxel

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH666897A5 (fr) 1983-10-11 1988-08-31 Fidia Spa Fractions d'acide hyaluronique non inflammatoire, procedes et compositions pharmaceutiques.
IT1263393B (it) 1993-07-30 1996-08-05 Fidia Advanced Biopolymers Srl Processo per la preparazione e purificazione di acido ialuronico ad alto peso molecolare
NZ516873A (en) 2001-02-12 2003-11-28 Warner Lambert Co Compositions containing retinoids and erb inhibitors and their use in inhibiting retinoid skin damage
ITPD20020271A1 (it) 2002-10-18 2004-04-19 Fidia Farmaceutici Composti chimico-farmaceutici costituiti da derivati dei taxani legati covalentemente all'acido ialuronico o ai suoi derivati.
US20050080075A1 (en) * 2003-08-25 2005-04-14 Nichols M. James Formulations, conjugates, and combinations of drugs for the treatment of neoplasms
ITMI20071267A1 (it) 2007-06-22 2008-12-23 Fidia Farmaceutici Uso di coniugati dell'acido ialuronico nel trattamento locale di malattie cutanee iperproliferative
IT1402385B1 (it) 2010-09-09 2013-09-04 Fidia Farmaceutici Processo per la produzione di acido ialuronico in escherichia coli o bacillus subtilis
IT1402384B1 (it) 2010-09-09 2013-09-04 Fidia Farmaceutici Processo per la produzione di acido ialuronico in escherichia coli o bacillus megaterium
EP3760707B1 (en) 2011-11-09 2025-11-19 Fibrobiologics, Inc. Fibroblasts for use in the treatment of degenerative disc disease
IT201600079633A1 (it) 2016-07-28 2018-01-28 Fidia Farm Spa Procedimento di preparazione e purificazione del sale sodico dell’acido ialuronico
CN110859962B (zh) 2019-11-25 2021-01-22 山东大学 巴比妥酸衍生物修饰的二硫化钼二维纳米材料及其应用

Also Published As

Publication number Publication date
PL3870233T3 (pl) 2024-05-06
US20210196833A1 (en) 2021-07-01
EP3870233B1 (en) 2023-12-06
KR20210083249A (ko) 2021-07-06
DK3870233T3 (da) 2024-02-05
US12465649B2 (en) 2025-11-11
CA3112188A1 (en) 2020-04-30
KR102913965B1 (ko) 2026-01-16
US20210268119A1 (en) 2021-09-02
CN119792555A (zh) 2025-04-11
FI3870233T3 (fi) 2024-02-07
JP2022503771A (ja) 2022-01-12
HRP20240188T1 (hr) 2024-05-10
HUE066288T2 (hu) 2024-07-28
RS65193B1 (sr) 2024-03-29
CN112805035A (zh) 2021-05-14
ES2971217T3 (es) 2024-06-04
US20240123077A1 (en) 2024-04-18
SI3870233T1 (sl) 2024-03-29
US20200397909A1 (en) 2020-12-24
MA63879B1 (fr) 2024-02-29
EP3870233A1 (en) 2021-09-01
SMT202400021T1 (it) 2024-03-13
IT201800009731A1 (it) 2020-04-25
LT3870233T (lt) 2024-02-26
JP7518815B2 (ja) 2024-07-18
WO2020084525A1 (en) 2020-04-30
PT3870233T (pt) 2024-02-01

Similar Documents

Publication Publication Date Title
MX2025000105A (es) Inhibidor de kras g12c para el tratamiento del cancer
PH12021551792A1 (en) Bi-ligand drug conjugate and use thereof
AR059982A1 (es) Terapia tumoral con un anticuerpo contra el factor de crecimiento endotelial vascular y un anticuerpo contra el receptor del factor de crecimiento epitelial tipo 2 humano
BR112023006337A2 (pt) Produto farmacêutico, uso de um conjugado anticorpo anti-her2-fármaco ou um inibidor seletivo de parp1, e, método de tratamento do câncer
AR072442A1 (es) Metodo para la terapia del cancer, uso, kit
CY1114215T1 (el) Φαρμακευτικες συνθεσεις διαλυματος για υπο πιεση εισπνευστηρες μετρουμενης δοσης
NZ595767A (en) Composition for the treatment of prostate cancer
ZA202209896B (en) Sulfonamide or sulfinamide compound having effect of inducing brd4 protein degradation and pharmaceutical use thereof
FI3493812T3 (fi) Imetelstaatin ja venetoklaksin yhdistelmiä akuutin myelooisen leukemian hoitoa varten
MX2021015447A (es) Métodos de tratamiento del cáncer dirigidos a tumores fríos.
CL2021003034A1 (es) Métodos de tratamiento del síndrome de sjögren utilizando un inhibidor de la tirosina quinasa de bruton
MX2022016554A (es) Métodos de tratamiento del cáncer mediante derivados heteroaril-bifenil-amida.
EA202190308A1 (ru) Применение пролекарств рилузола для лечения болезни альцгеймера
CL2022000781A1 (es) Tratamientos cognitivos medicinales
MX2025010161A (es) Conjugados de anticuerpo-farmaco que comprenden derivados de trabectedina y lurbinectedina
WO2021242844A8 (en) Grk2 inhibitors and uses thereof
MX2022002555A (es) Conjugados de farmaco de anticuerpo de union a receptor de tipo ii de la hormona anti-mulleriana humana (amhrii) y uso de los mismos en el tratamiento de canceres.
EA201991069A1 (ru) Комбинированная терапия ингибитором фосфоинозитид-3-киназы и связывающим цинк агентом
AR126393A1 (es) Terapia combinada para el tratamiento de enfermedades hepáticas
FI3870233T3 (fi) Paklitakseli-Hyaluronihapon konjugaatti käytettäväksi ei-lihasinvasiivisen virtsarakon syövän hoidossa
MX2022011171A (es) Compuestos con actividad inmunomodulatoria y usos terapeuticos de estos.
CL2024002761A1 (es) Tratamiento del glioma de bajo grado con mirdametinib
MX2025015101A (es) Un metodo para el tratamiento de tumores solidos con un conjugado anticuerpo-farmaco dirigido a claudina 18.2
JP2022503771A5 (cg-RX-API-DMAC7.html)
CL2023001783A1 (es) Métodos para el tratamiento de la acondroplasia